Grant: Master's Award: Canada Graduate Scholarships
McMaster University
$17,500.00
Safety and efficacy of tranexamic acid in general surgery: a substudy of the perioperative ischemia evaluation 3 (POISE-3) trial
FY 2022-23
Summary
Bleeding around the time of surgery leads to worse outcomes including higher morbidity, mortality, need for blood transfusion, and healthcare costs. Tranexamic acid (TXA) is a low-cost drug that can be rapidly administered intravenously to stop or prevent bleeding. There is a theoretical risk of blood clots, given its mechanism, but current evidence supports TXA use in the peri-operative setting to reduce bleeding risk. However, there lacks robust evidence for TXA utilization specifically among general surgery patients. This has limited the uptake of TXA use by general surgeons who have expressed need for dedicated evidence within their field of practice.
The randomized controlled trial (RCT) entitled “Tranexamic Acid in Patients Undergoing Noncardiac Surgery”, or Perioperative Ischemic Evaluation 3 (POISE-3) trial, was led by our research group and recently published in the New England Journal of Medicine. This study included 9535 patients undergoing noncardiac surgery, among which 3542 patients underwent general surgery. Patients were randomized to receive TXA or placebo with results demonstrating decreased perioperative bleeding with TXA use.
The study herein will be a sub-study of this POISE-3 trial with the objective to investigate the safety and efficacy of tranexamic acid (TXA) versus placebo in preventing perioperative bleeding among patients undergoing general surgery. We expect TXA to have a similar effect in patients undergoing non-general surgery compared to patients undergoing general surgery, that is, TXA utilization in general surgery will safely reduce the risk of perioperative bleeding. As the largest study in the field, it will provide high-impact evidence for TXA use among general surgeons in clinical practice to improve surgical outcomes.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
486153
Name
Park Lily J
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Safety and efficacy of tranexamic acid in general surgery: a substudy of the perioperative ischemia evaluation 3 (POISE-3) trial
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
General Surgery; Perioperative Bleeding; Perioperative Medicine; Thrombosis; Tranexamic Acid; Transfusion
Abstract
Bleeding around the time of surgery leads to worse outcomes including higher morbidity, mortality, need for blood transfusion, and healthcare costs. Tranexamic acid (TXA) is a low-cost drug that can be rapidly administered intravenously to stop or prevent bleeding. There is a theoretical risk of blood clots, given its mechanism, but current evidence supports TXA use in the peri-operative setting to reduce bleeding risk. However, there lacks robust evidence for TXA utilization specifically among general surgery patients. This has limited the uptake of TXA use by general surgeons who have expressed need for dedicated evidence within their field of practice.
The randomized controlled trial (RCT) entitled “Tranexamic Acid in Patients Undergoing Noncardiac Surgery”, or Perioperative Ischemic Evaluation 3 (POISE-3) trial, was led by our research group and recently published in the New England Journal of Medicine. This study included 9535 patients undergoing noncardiac surgery, among which 3542 patients underwent general surgery. Patients were randomized to receive TXA or placebo with results demonstrating decreased perioperative bleeding with TXA use.
The study herein will be a sub-study of this POISE-3 trial with the objective to investigate the safety and efficacy of tranexamic acid (TXA) versus placebo in preventing perioperative bleeding among patients undergoing general surgery. We expect TXA to have a similar effect in patients undergoing non-general surgery compared to patients undergoing general surgery, that is, TXA utilization in general surgery will safely reduce the risk of perioperative bleeding. As the largest study in the field, it will provide high-impact evidence for TXA use among general surgeons in clinical practice to improve surgical outcomes.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Park, Lily J
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~